Disclosure Of Entity's Operating Segments [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166253

Concept 2022-01-01 to
2022-12-31
As at
2022-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
Disclosure of entity's operating segments [text block]
5
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
2,951 EUR
3,096 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method
130,000 EUR
191,000 EUR
Tax expense (income)
4,000 EUR
297,000 EUR
Profit (loss) before tax
10,766 EUR
11,282 EUR
Profit (loss)
10,770 EUR
11,579 EUR
Assets
61,864 EUR
63,444 EUR
Investments accounted for using equity method
3,948 EUR
4,079 EUR
Liabilities
6,819 EUR
15,388 EUR
Cash flows from (used in) operating activities
13,154 EUR
11,250 EUR
Cash flows from (used in) investing activities
1,239 EUR
3,075 EUR
Cash flows from (used in) financing activities
7,838 EUR
62,000 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.